TAMOXIFEN — 10 mg / 20 mg tablet

Tamoxifen is a selective oestrogen receptor modulator (SERM). It competitively inhibits oestrogen binding to oestrogen receptors in breast tissue, thereby blocking oestrogen‑dependent tumour growth. It is the cornerstone of endocrine therapy for hormone receptor‑positive (HR+) breast cancer in both pre‑ and post‑menopausal women. Off‑label / indication‑specific uses include male breast cancer and ovulation induction, though these are not universally approved.

Unlike aromatase inhibitors (which lower oestrogen levels), tamoxifen acts directly on the receptor. It has partial agonist effects in other tissues (bone, endometrium, liver), which explains its distinct safety profile—preserved bone density but increased uterine and thromboembolic risks.

Because of its partial agonist activity and potential for serious adverse reactions, tamoxifen requires strict medical supervision. Baseline and regular gynaecological assessments, along with monitoring for signs of thrombosis, are mandatory. Labelling, dosing intervals, and approved indications can differ between countries (e.g. US, UK, India); always follow locally approved product information.